Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the successful transfer and rewrite of all its intellectual property protections to cover a newly developed crystalline form of its lead drug …
Annovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has announced its participation in the prestigious Alzheimer’s Association International Conference (AAIC) 2025. The global event, set to take place from July …
Annovis Bio to Present Key Findings at Alzheimer’s Association International Conference Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced it has received an “Acceptance Letter” from the New York Stock Exchange (NYSE), confirming the NYSE’s approval of the Company’s plan …
Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced a live webcast with Maria Maccecchini, Ph.D., President and CEO, to provide updates and answer audience questions.
Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) unveiled significant progress in its efforts to combat neurodegenerative diseases with updates on its pivotal Phase 3 clinical trial and solid financial …
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has named Hui Liu as Director of Biostatistics to bolster its efforts as the company progresses with its pivotal Phase 3 Alzheimer’s …
Annovis Bio Appoints Hui Liu as Director of Biostatistics Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has received a notice from the New York Stock Exchange (NYSE) regarding its non-compliance with continued listing standards under Section 802.01B of the …
Annovis Bio Receives Non-Compliance Notice from NYSE Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biopharmaceutical company, is set to showcase significant advancements in its treatments for Alzheimer’s disease (AD) and Parkinson’s disease (PD) at the …
Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has shared its corporate updates and financial results for the fourth quarter and full year of 2024, highlighting significant advancements in its clinical …
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) is set to participate in the 13th Alzheimer’s & Parkinson’s Drug Development Summit, taking place March 18-20 in Boston, Massachusetts. The company will …
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit Read More